CXCR4 and hematologic disorder: For instance, the small molecule CXCR4 inhibitor Plerixafor exhibits potential for mobilizing hematopoietic stem cells, and the inhibition of CXCL12/CXCR4 signaling may serve as an adjuvant in the treatment of hematologic malignancies and solid tumors [183–185].